Kenvue Inc.

Kimberly-Clark raised its quarterly dividend from $1.26 to $1.28 per share in January 2026, bringing the annual payout to $5.12 per share and a yield of about 4.6% with the stock near $110. The company has increased its dividend for 54 consecutive years and paid dividends for 92 years, supported by essential brands like Huggies, Kleenex, and Scott that hold No. 1 or No. 2 positions in roughly 70 countries. Cash from operations including discontinued operations reached $1.7 billion in the first half of 2026, up from $1.1 billion a year earlier, while capital spending rose to $776 million from $401 million and dividends paid totaled $843 million. Management expects about $2 billion in adjusted free cash flow for 2026, roughly in line with 2025, despite plans to spend about $1.3 billion on capital investments. The pending Kenvue acquisition, expected to close in the fourth quarter of 2026, is projected to add about $1.9 billion in cost synergies and another $500 million in profit from revenue synergies within three to four years of closing, though integration risks remain.

Kenvue Inc. remains a closely watched consumer health name as investors weigh trusted brands, improving margins and a major pending transaction. In the first quarter of 2026, adjusted gross margin expanded 80 basis points to 60.8% and adjusted operating margin improved 420 basis points to 24%, driven by supply-chain productivity and cost optimization actions. Skin Health and Beauty net sales increased 8.4%, with organic sales up 5%, supported by volume growth and innovation such as Neutrogena's entry into sun care in select EMEA markets. The pending cash-and-stock combination with Kimberly-Clark Corporation, under which Kenvue shareholders are expected to receive 0.14625 Kimberly-Clark shares plus $3.50 in cash per Kenvue share, has received shareholder approvals and U.S. antitrust clearance, with closing expected in the second half of 2026. The stock currently carries a Zacks Rank #3 (Hold), with Value, Growth and VGM Scores of C and a Momentum Score of D, reflecting a balanced near-term view.

Kenvue declared a quarterly cash dividend of $0.21 per share, a 1.2 percent increase from the prior quarterly dividend. The dividend is payable on August 26, 2026, to shareholders of record as of the close of business on August 12, 2026.

Kenvue received FDA approval for Tylenol with Naproxen, a new over-the-counter pain reliever offering up to 12 hours of pain relief and slated for distribution across major U.S. retailers. The approval adds a differentiated option to Kenvue's Self Care portfolio and could strengthen the Tylenol brand's position in the competitive pain relief category. The company's upcoming second quarter 2026 results on August 6, 2026, will provide an updated view on Self Care performance and how quickly new launches like Tylenol with Naproxen contribute alongside existing brands. Kenvue's investment narrative projects $16.7 billion revenue and $2.3 billion earnings by 2029, with a fair value estimate of $19.50 per share. Community valuations for Kenvue range from $19.50 to $32.38 per share, reflecting divergent expectations about the impact of new products on the company's growth trajectory.

The FDA has approved Kenvue's TYLENOL with Naproxen, the first and only over-the-counter fixed-dose combination of acetaminophen and naproxen sodium for pain relief. The product combines 650 mg of acetaminophen with 220 mg of naproxen sodium, offering fast-acting relief in under 30 minutes and up to 12 hours of relief in a single dose. The approval is supported by eight clinical studies showing superior pain relief compared to either ingredient alone, and the FDA has granted three years of exclusivity. Kenvue plans to make the product available soon at major U.S. retailers nationwide.

Jim Cramer highlighted Kimberly-Clark as a defensive holding on CNBC's Mad Money, citing its acquisition of Kenvue, Johnson & Johnson's former consumer health business. The deal adds brands like Tylenol, Neutrogena, Listerine, and Band-Aids, creating a high-margin powerhouse with steady cash flow through economic cycles. Kimberly-Clark trades at roughly 14 times earnings, near its lowest multiple in a decade, and offers a 4.74% dividend yield after raising its quarterly payout to $1.28 per share, backed by 54 consecutive years of dividend increases. Cramer sees the stock as a long-term opportunity with potential upside from the Kenvue integration, though he does not expect a blowout second-quarter report on August 4th. Institutional investors own about 93% of the company, while a 14.5% short float could fuel a squeeze if integration results beat expectations.

Kimberly-Clark, a Dividend King with 54 consecutive years of dividend increases, offers a 4.7% yield and is positioned for solid returns following a strategic shift. The company recently formed a joint venture called Arbex with pulp supplier Suzano, offloading its lower-margin paper-towel and tissue business to focus on higher-margin personal-care products while retaining licensing royalties. This move frees up resources to integrate its pending acquisition of Kenvue, a consumer health company spun off from Johnson & Johnson in 2023, which Kimberly-Clark expects will generate approximately $1.9 billion in cost synergies and roughly $500 million in profit from revenue synergies within three to four years of closing. Analysts have a median price target of $113 per share, implying 5% upside, and the stock trades at 14 times earnings.

Kimberly-Clark has risen 13.7% year to date, outpacing the S&P 500 and Nasdaq Composite, and offers a 4.5% dividend yield. The company’s recession-resistant portfolio of household brands like Huggies and Kleenex supports consistent demand, while management expects to recover input cost inflation and expand margins over time. A pending acquisition of consumer health company Kenvue, approved by shareholders, is set to close before year-end and is projected to deliver $2.1 billion in annual run rate synergies by the second year. Kimberly-Clark trades at 15.2 times consensus 2026 earnings estimates, well below its 10-year median price-to-earnings ratio of 21.9, and has raised its dividend for 54 consecutive years.

Three healthcare stocks trading under $30—Kenvue, Pfizer, and Viatris—offer value setups heading into the second half of 2026. Kenvue, the consumer health company behind Tylenol and Neutrogena, closed at $19.83 and is being acquired by Kimberly-Clark for $3.50 cash plus 0.14625 Kimberly-Clark shares, with shareholder approval secured and the deal expected to close in the second half of 2026. Pfizer trades at $24.32 with a 7.2% dividend yield and a forward P/E of 8, having reaffirmed full-year 2026 revenue guidance of $59.5 to $62.5 billion and adjusted EPS of $2.80 to $3.00, supported by a pipeline that includes roughly 20 pivotal trial starts this year. Viatris, at $16.70, carries a forward P/E of 7 and has three FDA PDUFA decisions due before year-end 2026, while management reaffirmed 2026 guidance and is executing a restructuring targeting $600 to $700 million in annualized cost savings. Each name carries risks including deal execution, patent cliffs, and generic pricing pressure, but all three have reaffirmed 2026 outlooks and identifiable catalysts.

Kimberly-Clark has announced a planned $48.7 billion acquisition of Kenvue, a deal that would integrate Kenvue into Kimberly-Clark's consumer products portfolio. Kenvue, which trades on the NYSE under the ticker KVUE, last closed at $19.33, with the stock up 2.8% over the past week and 11.4% over the past month. Over the past year the share price declined 3.2% and over three years it declined 15.0%. Investors are watching for updates on how the deal could affect Kenvue's operations, capital allocation, and brand priorities, as well as any guidance on margins, capital spending, and future capital returns.

Zacks Investment Research recommends five beauty and cosmetics stocks for a stable portfolio in the second half of 2026, all carrying a Zacks Rank of 1 (Strong Buy) or 2 (Buy). The picks are Estée Lauder, Helen of Troy, Nu Skin Enterprises, Kenvue, and Interparfums. Estée Lauder, the sole Strong Buy, is expected to see earnings grow 31.9% in its fiscal year ending June 2027, driven by its Profit Recovery and Growth Plan and digital expansion. Kenvue's earnings estimate has risen 5.5% over the past 60 days, with projected revenue growth of 3.2%. The other three companies face near-term revenue or earnings declines, but are supported by strategic initiatives such as portfolio optimization and channel expansion.

Hormel Foods has returned 9.8% year-to-date, outperforming the average 8.2% gain of the Consumer Staples sector, which comprises 173 stocks and ranks 15th out of 16 Zacks sectors. The company holds a Zacks Rank of 2, or Buy, and its full-year earnings consensus estimate has risen 4.6% over the past quarter. Within its Food - Meat Products industry, which has lost an average of 2.5% this year, Hormel's performance is notably stronger. Kenvue, another Consumer Staples stock, has returned 9.9% year-to-date and also carries a Zacks Rank of 2, with its current-year EPS estimate up 5.3% over three months.

The Motley Fool identifies Church & Dwight, Keurig Dr Pepper, and Kenvue as consumer staples companies offering predictable demand for a $1,000 investment during uncertain markets. Church & Dwight beat first-quarter 2026 guidance with 5% organic sales growth driven entirely by volume, and it acquired Miss Mouth's Messy Eater for $325 million in May. Keurig Dr Pepper's stock is down nearly 29% from its 2025 peak despite beating revenue estimates for four straight quarters, while its energy drink portfolio including Ghost, C4, Venom, and Black Rifle Energy is expected to generate well over $1 billion in annual retail sales. Kenvue's skin health and beauty division grew 8.4% in the first quarter of 2026, and its pending merger with Kimberly-Clark is expected to close in the second half of the year, creating one of the largest consumer health and personal care platforms globally.

Kenvue, the consumer health spinoff from Johnson & Johnson, is trading around $18.32 per share, well below the $21.01 per share total consideration offered in its pending $40 billion mega-merger with Kimberly-Clark. The deal, already approved by shareholders of both companies but still subject to foreign regulatory approvals, would give Kenvue investors $3.50 in cash plus 0.14625 Kimberly-Clark shares for each Kenvue share held. The combined company expects to capture roughly $2.1 billion in run rate cost synergies by giving local markets full profit-and-loss ownership while leveraging Kimberly-Clark’s global supply chain. Kenvue, a Dividend King with 63 consecutive years of payout increases, currently yields 4.53% and owns iconic brands such as Tylenol, Listerine, Neutrogena, and Band-Aid, while its first-quarter revenue rose 4.5% year over year to $3.9 billion and earnings per share jumped 47% to $0.25.